New compounds for tailored therapy against MLL-rearranged leukaemia

用于针对 MLL 重排白血病的定制疗法的新化合物

• 批准号: nhmrc : 630621
• 负责人: Dr Michelle Henderson
• 金额: $ 21.76万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-compounds-tailored-rearranged-leukaemia/94802
• 关键词: New; compounds; tailored; therapy; against

Some of the worst leukaemia survival rates are found in children and adults whose leukaemias display abnormalities of the MLL gene and alternative therapies are therefore urgently required for these patients. The aim of this project is to develop new compounds that specifically inhibit this abnormal gene and in turn inhibit the growth of these cells in the patient. In this way we hope to provide new and more effective therapies for patients affected with this aggressive type of leukaemia.

一些最差的白血病生存率发现在儿童和成人的白血病显示异常的MLL基因和替代疗法，因此迫切需要为这些患者。该项目的目的是开发新的化合物，专门抑制这种异常基因，从而抑制这些细胞在患者体内的生长。通过这种方式，我们希望为这种侵袭性白血病患者提供新的和更有效的治疗方法。